MeiraGTx Holdings plc (FRA:328)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.23B +128.6% |
| Revenue (ttm) | 347.93M +948.3% |
| Net Income | 69.13M |
| EPS | 0.82 |
| Shares Out | n/a |
| PE Ratio | 17.76 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 12.70 |
| Previous Close | 12.80 |
| Day's Range | 12.70 - 12.70 |
| 52-Week Range | 5.85 - 13.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About MeiraGTx Holdings
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal ... [Read more]
Financial Performance
In 2025, MeiraGTx Holdings's revenue was $81.39 million, an increase of 144.57% compared to the previous year's $33.28 million. Losses were -$114.20 million, -22.73% less than in 2024.
Financial numbers in USD Financial StatementsNews
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patie...
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade...
MeiraGTx Holdings Earnings release: Q2 2026
MeiraGTx Holdings released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MeiraGTx Holdings Quarterly report: Q2 2026
MeiraGTx Holdings has published its Q2 2026 quarterly earnings report on August 13, 2026.
MeiraGTx Holdings Slides: Corporate presentation
MeiraGTx Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical r...
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Co...
MeiraGTx price target raised to $26 from $25 at RBC Capital
RBC Capital analyst Luca Issi raised the firm’s price target on MeiraGTx (MGTX) to $26 from $25 and keeps an Outperform rating on the shares. The company has announced a…
MeiraGTx announces $400M investment by Oberland Capital
MeiraGTx (MGTX) announced that it has entered into an agreement with Oberland Capital for an investment of up to $400M in the company, including up to $375M in non-dilutive capital…
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered into...
MeiraGTx Holdings Transcript: AGM 2026
The meeting covered board introductions, election of directors, and auditor ratification. All proposals passed, with final vote results to be published soon. No shareholder questions were raised during the meeting.
MeiraGTx Holdings Transcript: Jefferies Global Healthcare Conference 2026
Four late-stage gene therapy programs are advancing, including a transformative xerostomia treatment nearing pivotal data and a reacquired XLRP program with strong secondary efficacy. RiboSwitch technology enables oral gene control, with a leptin program entering the clinic this year.
MeiraGTx Holdings Slides: FY 2026
MeiraGTx Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
MeiraGTx Holdings Slides: Corporate presentation
MeiraGTx Holdings has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
MeiraGTx reports Q1 EPS (57c), consensus (45c)
Reports Q1 revenue $293,000 vs. $1.93M last year. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx (MGTX) – we are now in a position to…
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostom...
MeiraGTx Holdings Earnings release: Q1 2026
MeiraGTx Holdings released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
MeiraGTx Holdings Quarterly report: Q1 2026
MeiraGTx Holdings has published its Q1 2026 quarterly earnings report on May 14, 2026.
MeiraGTx Holdings Transcript: Bank of America Global Healthcare Conference 2026
Major progress includes regaining RPGR rights, advancing pivotal xerostomia and Parkinson's programs, and leveraging in-house manufacturing to accelerate regulatory filings. Durable clinical data and strong physician networks support targeted commercialization and premium pricing.
MeiraGTx Holdings Proxy statement: Proxy filing
MeiraGTx Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
MeiraGTx Holdings Proxy statement: Proxy filing
MeiraGTx Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
MeiraGTx price target raised to $30 from $26 at Piper Sandler
Piper Sandler raised the firm’s price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company’s long-term data update in xerostomia…
MeiraGTx price target raised to $24 from $16 at RBC Capital
RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $24 from $16 and keeps an Outperform rating on the shares. The company’s 3-year follow-up data from the Phase…
MeiraGTx announces three-year data from Phase 1 AQUAx study
MeiraGTx (MGTX) announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia. “Today we are very pleased to…
MeiraGTx Holdings Transcript: KOL event
Three-year phase I data for AAV-AQP1 in persistent RIX show robust, durable efficacy and safety, with transformative, disease-modifying effects and high physician and payer support. The therapy targets a large, concentrated market, with pivotal data and BLA filing expected in 2027 and a U.S. launch in 2028.